Everolimus
Sign in to save this workspacePrimary targets: FKBP12, MTOR_FRAP1 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.706
CATDS
0.024
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Everolimus. Strongest target: PKMYT1 at 33.8% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PKMYT1 | 33.8% | 66.2% |
| 2 | CAMKK2 | 28.8% | 71.2% |
| 3 | PDK2_PDHK2 | 28.6% | 71.4% |
| 4 | ERN1_IRE1 | 25.3% | 74.7% |
| 5 | STK33 | 22.2% | 77.8% |
| 6 | ALK2_ACVR1 | 21.6% | 78.4% |
| 7 | GSK3A | 21.5% | 78.5% |
| 8 | MLK3_MAP3K11 | 21.1% | 78.9% |
| 9 | MUSK | 19.4% | 80.6% |
| 10 | EGFR | 17.8% | 82.2% |
| 11 | WEE1 | 17.6% | 82.4% |
| 12 | CK1D | 17.5% | 82.5% |
| 13 | TRPM7_CHAK1 | 16.7% | 83.3% |
| 14 | CTK_MATK | 16.4% | 83.6% |
| 15 | NEK8 | 16.4% | 83.6% |
| 16 | ABL1 | 16.0% | 84.0% |
| 17 | TESK1 | 15.8% | 84.2% |
| 18 | TTBK2 | 15.6% | 84.4% |
| 19 | ROS_ROS1 | 15.6% | 84.4% |
| 20 | PHKG1 | 15.6% | 84.4% |
Selectivity landscape
Where Everolimus sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Everolimus.
Atlas insights for Everolimus
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 328.16 | |
| ALLOGRAFT_REJECTION | 674.90 | |
| ANDROGEN_RESPONSE | 306.52 | |
| ANGIOGENESIS | 109.48 | |
| APICAL_JUNCTION | 797.97 | |
| APICAL_SURFACE | 110.76 | |
| APOPTOSIS | 994.03 | |
| BILE_ACID_METABOLISM | 103.80 | |
| CHOLESTEROL_HOMEOSTASIS | 276.72 | |
| COAGULATION | 103.51 | |
| COMPLEMENT | 516.36 | |
| DNA_REPAIR | 310.36 | |
| E2F_TARGETS | 858.16 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 281.52 | |
| ESTROGEN_RESPONSE_EARLY | 467.18 | |
| ESTROGEN_RESPONSE_LATE | 329.40 | |
| FATTY_ACID_METABOLISM | 88.62 | |
| G2M_CHECKPOINT | 675.22 | |
| GLYCOLYSIS | 363.30 | |
| HEDGEHOG_SIGNALING | 103.01 | |
| HEME_METABOLISM | 197.44 | |
| HYPOXIA | 651.72 | |
| IL2_STAT5_SIGNALING | 428.95 | |
| IL6_JAK_STAT3_SIGNALING | 569.05 | |
| INFLAMMATORY_RESPONSE | 548.41 | |
| INTERFERON_ALPHA_RESPONSE | 107.63 | |
| INTERFERON_GAMMA_RESPONSE | 675.11 | |
| KRAS_SIGNALING_DN | 140.41 | |
| KRAS_SIGNALING_UP | 341.81 | |
| MITOTIC_SPINDLE | 821.53 | |
| MTORC1_SIGNALING | 390.20 | |
| MYC_TARGETS_V1 | 531.62 | |
| MYC_TARGETS_V2 | 177.67 | |
| MYOGENESIS | 443.79 | |
| NOTCH_SIGNALING | 89.42 | |
| OXIDATIVE_PHOSPHORYLATION | 110.19 | |
| P53_PATHWAY | 606.66 | |
| PANCREAS_BETA_CELLS | 63.79 | |
| PEROXISOME | 137.12 | |
| PI3K_AKT_MTOR_SIGNALING | 1042.91 | |
| PROTEIN_SECRETION | 194.73 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 64.49 | |
| SPERMATOGENESIS | 248.33 | |
| TGF_BETA_SIGNALING | 328.78 | |
| TNFA_SIGNALING_VIA_NFKB | 669.44 | |
| UNFOLDED_PROTEIN_RESPONSE | 173.11 | |
| UV_RESPONSE_DN | 532.11 | |
| UV_RESPONSE_UP | 449.64 | |
| WNT_BETA_CATENIN_SIGNALING | 397.10 | |
| XENOBIOTIC_METABOLISM | 204.02 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.880 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.856 |
| SRR1443713 | GTEX | 0.849 |
| SRR12202498 | — | 0.841 |
| aMVAC.P_005_TURBT_S223 | — | 0.840 |
Annotations
Sign in to read and post annotations.
Loading…